Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,165.08
(
0.80%
)
US TECH 100
26,538.40
(
1.85%
)
Dow Jones
49,247.66
(
-0.13%
)
Brent Oil
100.66
(
0.00%
)
Bitcoin
77,278.31
(
-0.25%
)
News Focus
News Focus
Post# of 257443
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122886
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: None

Thursday, 10/11/2012 7:47:03 AM

Thursday, October 11, 2012 7:47:03 AM

Post# of 257443
Kithera (KYTH) IPO’s at $16/sh, raising approximately $75 (assuming exercise of underwriter’s option):

http://finance.yahoo.com/news/kythera-biopharmaceuticals-announces-pricing-initial-110000848.html

The company’s lead program is ATX-101, an injectable drug in phase-3 for cosmetic treatment of double chins. In a 2010 deal, Bayer licensed the rights to ATX-101 outside the US and Canada (http://www.kytherabiopharma.com/newsroom/article/bayer-agreement-ATX-101 ).

Other pipeline products include ATX-104 for “facial contouring” and ATX-102 for “pigmentation modulation.”

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now